Spots Global Cancer Trial Database for monoclonal antibody therapy
Every month we try and update this database with for monoclonal antibody therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT00265928 | Lymphoma | bortezomib rituximab antibody therap... biological ther... enzyme inhibito... monoclonal anti... | 18 Years - | National Cancer Institute (NCI) | |
| Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL | NCT01145209 | Small Lymphocyt... CLL (Chronic Ly... | Fludarabine Pho... Ofatumumab Cyclophosphamid... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00666692 | Non-small Cell ... | M200 (Volocixim... | 18 Years - | Abbott | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease | NCT00515892 | Leukemia Non-Hodgkin's L... NHL | Immunotoxin the... CAT-8015 Immuno... Biological ther... Antibody Therap... Monoclonal Anti... | 18 Years - | Cambridge Antibody Technology | |
| BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma | NCT00077493 | Leukemia Lymphoma | BL22 immunotoxi... antibody-drug c... immunotoxin the... monoclonal anti... | 6 Months - 24 Years | MedImmune LLC | |
| A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome | NCT00217594 | Myelodysplastic... | Alemtuzumab (Ca... | 18 Years - 72 Years | National Institutes of Health Clinical Center (CC) | |
| Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease | NCT00515892 | Leukemia Non-Hodgkin's L... NHL | Immunotoxin the... CAT-8015 Immuno... Biological ther... Antibody Therap... Monoclonal Anti... | 18 Years - | Cambridge Antibody Technology | |
| Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia | NCT00366418 | Refractory Chro... | Rituximab | 21 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer | NCT00253526 | Adenocarcinoma ... Recurrent Pancr... Stage I Pancrea... Stage II Pancre... Stage III Pancr... | bevacizumab gemcitabine hyd... adjuvant therap... anti-cytokine t... antiangiogenesi... antibody therap... biological ther... chemotherapy conventional su... growth factor a... monoclonal anti... surgery | 18 Years - | National Cancer Institute (NCI) | |
| A Phase 1b Study With Volociximab in Combination With Carboplatin, Paclitaxel, and Bevacizumab in First-line, Advanced Non-small Cell Lung Cancer (NSCLC) | NCT00666692 | Non-small Cell ... | M200 (Volocixim... | 18 Years - | Abbott | |
| Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | NCT00439231 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide | 21 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
